Exelixis, Inc. Looks Ahead -- but the 3rd Quarter Wasn't Too Shabby

Exelixis, Inc. Looks Ahead -- but the 3rd Quarter Wasn't Too Shabby

Exelixis (NASDAQ: EXEL), the biotech once left for dead by quite a few investors, continues its resurgence with another solid quarter of sales of its kidney cancer drug Cabometyx. Of course, the third quarter almost doesn't matter that much since most of the biotech's current valuation is supported by potential future sales as Exelixis hopes to expand drug treatment of first-line kidney cancer as well as liver cancer.

Metric

Q3 2017

Continue reading

Source: Fool.com